The DOI matches its Crossref record.
High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses
Abstract
SETTING: Niger National Tuberculosis Programme. Regions supported by the Damien Foundation. OBJECTIVE: To evaluate the effectiveness of a short-course standardised treatment regimen for patients with proven multidrug-resistant tuberculosis (MDR-TB) previously untreated with second-line drugs. METHODS: Prospective study including all patients enrolled from 2008 to 2010. The 12-month standardised regimen comprised high doses of gatifloxacin, clofazimine, ethambutol and pyrazinamide throughout, supplemented by kanamycin, prothionamide and medium-high doses of isoniazid during the intensive phase of a minimum of 4 months. Patients were monitored using sputum smear and culture at start of treatment and every 2 months. Cured patients were followed up 6-monthly for 24 months. RESULTS: Sixty-five patients with MDR-TB were included and analysed. One of 58 patients tested for human immunodeficiency virus (1.7%) infection was positive. Twenty-five patients (39.7%) were severely affected (body mass index ⩿16 kg/m(2)). Cure was achieved in 58 patients (89.2%, 95%CI 81.7-96.7), 6 died and 1 defaulted. All 49 patients assessed at the 24-month follow-up after cure remained smear- and culture-negative. The main adverse events were vomiting (26.2%) and hearing impairment (20%), but no treatment had to be stopped. CONCLUSION: Standardised 12-month treatment for MDR-TB was highly effective and well tolerated in patients not previously exposed to second-line drugs in Niger.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Furin, J., Cox, H., & Pai, M. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30308-3 · Cited by 873
Dheda, K., Gumbo, T., Maartens, G., Dooley, K. E., McNerney, R., Murray, M., Furin, J., Nardell, E. A., London, L., Lessem, E., et al. (2017) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(17)30079-6 · Cited by 684
Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline
Nahid, P., Mase, S. R., Migliori, G. B., Sotgiu, G., Bothamley, G. H., Brozek, J. L., Cattamanchi, A., Cegielski, J. P., Chen, L., Daley, C. L., et al. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201909-1874st · Cited by 462
World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update
Falzon, D., Schünemann, H. J., Harausz, E., González-Angulo, L., Lienhardt, C., Jaramillo, E., & Weyer, K. (2017) · European Respiratory Journal · doi:10.1183/13993003.02308-2016 · Cited by 420
Tiberi, S., du Plessis, N., Walzl, G., Vjecha, M. J., Rao, M., Ntoumi, F., Mfinanga, S., Kapata, N., Mwaba, P., McHugh, T. D., et al. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(18)30110-5 · Cited by 396
Metadata
- Authors
- Piubello, A., Harouna, S. H., Souleymane, M. B., Boukary, I., Morou, S., Daouda, M., Hanki, Y., & Van Deun, A.
- Venue
- The International Journal of Tuberculosis and Lung Disease
- Published
- 2014-10-01
- Volume
- 18
- Issue
- 10
- Pages
- 1188-1194
- ISSN
- 1027-3719 (ISSN-L)
- 1815-7920
- OpenAlex
- W2007102363
- Cited by
- 226
- References
- 0
- FWCI
- 17.96
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses. https://app.cochat.ai/papers/10.5588/ijtld.13.0075
- The paper
- Piubello, A., Harouna, S. H., Souleymane, M. B., Boukary, I., Morou, S., Daouda, M., Hanki, Y., & Van Deun, A. (2014). High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses. The International Journal of Tuberculosis and Lung Disease. https://doi.org/10.5588/ijtld.13.0075
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.